The global thyroid gland disorder market was valued at $2,057 million in 2017, and is estimated to reach $2,771 million at a CAGR of 3.8% from 2018 to 2025. Thyroid gland disorder treatments are indicated for thyroid disorders that occur in the thyroid gland of a human body. Thyroid disorder is defined as an abnormal release of thyroid hormones that play a key role in the regulation of metabolism. The thyroid disease occurs mainly due to a deficiency of iodine in the body.
Rise in the incidence of thyroid gland disorder, increase in the number of disease awareness programs especially in the developing countries, and development of effective combination drug therapies to treat thyroid gland disorder majorly drive the growth of the global thyroid gland disorder treatment market. However, side effects of the drugs leading to low adherence and stringent government regulations for the approval of combination of therapies hamper the market growth. Presence of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders help to open new avenues for the growth of the thyroid gland disorder treatment market in the near future.
The global thyroid gland disorder treatment market is segmented based on disease type, drug type, route of administration, distribution channel, and region. Based on disease type, the market is bifurcated into hypothyroidism and hyperthyroidism. Based on drug type, the market is categorized into levothyroxine, liothyronine, propylthiouracil, imidazole-based compounds, and others. Based on route of administration, the market is classified into oral, intravenous, and others. Based on distribution channel, the market is categorized into wholesaler or distributor, retailer, mail-order pharmacy, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to disease type, drug type, route of administration, distribution channels, and region.
In-depth analysis based on region assists to understand the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Disease Type
Hypothyroidism
Hyperthyroidism
By Drug Type
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based Compound
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Wholesaler/Distributor
Retailer
Mail-order Pharmacy
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Asia-Pacific
Japan
China
Australia
India
South Korea
Others
LAMEA
Brazil
Saudi Arabia
South Africa
Others
KEY PLAYERS PROFILED
AbbVie Inc.
Pfizer Inc.
Merck & Co., Inc.
Lannett Company, Inc.
Allergan plc
Mylan N.V.
GlaxoSmithKline plc
Novartis AG
RLC LABS, Inc.
Abbott Laboratories
The other players of the thyroid gland disorder treatment market include (companies not profiled in the report):
Takeda Pharmaceutical Company Limited
Aspen
Amgen Inc.
Endo International plc
Acella Pharmaceuticals, LLC
Gemini Laboratories, LLC.
